Chronic Myeloid Leukemia (CML)
CML is a myeloproliferative neoplasm driven by the BCR-ABL fusion gene (Philadelphia chromosome). Tyrosine kinase inhibitors (TKIs) have transformed CML into a chronic, manageable disease with near-normal life expectancy.
Phases
- Chronic phase: majority at diagnosis; <10% blasts
- Accelerated phase: worsening counts, 10–19% blasts
- Blast crisis: ≥20% blasts resembling acute leukemia
Symptoms
- Fatigue, weight loss, night sweats
- Splenomegaly causing fullness or pain
- Elevated WBC counts found incidentally
- Bleeding or bone pain (advanced phases)
Diagnosis
- CBC showing leukocytosis, thrombocytosis, basophilia
- Bone marrow aspirate/biopsy with granulocytic hyperplasia
- Cytogenetics/FISH for t(9;22); quantitative PCR for BCR-ABL transcript
- Risk scores (Sokal, Hasford, ELTS) to guide therapy
Treatment
Tyrosine Kinase Inhibitors (TKIs)
- First-line: imatinib, dasatinib, nilotinib, bosutinib
- Second/third-line: ponatinib (effective for T315I mutation), asciminib (allosteric inhibitor)
- Choice based on risk profile, comorbidities, side-effect profiles
Monitoring
- Quantitative PCR for BCR-ABL every 3 months (response milestones at 3, 6, 12 months)
- Deep molecular response (MR4/MR4.5) required for treatment-free remission attempts
- Mutation analysis for resistance or rising transcript levels
Treatment-Free Remission (TFR)
- Consider after ≥3 years of TKI with sustained deep response
- Requires close monitoring (monthly PCR initially)
- Restart TKI if transcripts rise above defined thresholds
Advanced Phases
- More potent TKIs, combination therapy, or allogeneic stem cell transplant
- Blast crisis treated like acute leukemia plus TKI
Supportive Care
- Manage TKI side effects (edema, rash, myalgias, QT prolongation)
- Vaccinations, infection prophylaxis as needed
- Address cardiovascular risk factors (some TKIs increase risk)
Living with CML
- Track PCR results, TKIs, doses, side effects, lab values, and clinic visits
- Adherence is crucial; set reminders and manage pill burden
- Discuss family planning (TKIs teratogenic; require planning for pregnancy)
- Mental health support—anxiety about molecular results is common
Complications
- Disease progression if untreated or resistant
- TKI toxicity (cardiac, metabolic, pleural effusion)
- Secondary malignancies (rare)
- Allogeneic transplant risks (GVHD, infection)
Research & Future Directions
Efforts focus on deeper molecular responses, novel TKIs, immunotherapies, and cure strategies without lifelong medication.
Experimental & Emerging Treatments
- Asciminib: First-in-class STAMP inhibitor approved for resistant CML.
- Combination TKIs + Interferon/Immune Modulators: Aim to enhance TFR rates.
- Vaccines & Cellular Therapies: Target leukemia stem cells to eradicate minimal residual disease.
- Gene Editing: CRISPR-based approaches exploring BCR-ABL disruption in preclinical models.
Track CML with Diagnoza.care
Stay Molecularly Informed – Log PCR results, TKIs, side effects, labs, bone marrow biopsies, vaccination status, and transplant evaluations; capture adherence patterns; and let the AI companion flag deviations from response milestones for prompt hematology review.
Medical Disclaimer: Informational only. Follow your hematologist for TKI selection, molecular monitoring, mutation testing, and TFR planning.
Sources: National Comprehensive Cancer Network, European LeukemiaNet, American Society of Hematology